Interpretation: Most participants valued receiving incidental findings, but personal utility depended on the type of finding, and not all participants wanted to receive incidental results, regardless of the potential health implications. These results indicate that to maximize benefit, participant-level preferences should inform the decision about whether to return incidental findings.
C linical genomic sequencing technol ogies are on the verge of allowing individual ized care at reasonable cost. 1 Patients and their families will soon receive information from clinical sequencing that has implications for clin ical care, including information on consequences related to disease prognosis, treatment response or hereditary risk for disease. 2 Clinical sequenc ing can also generate incidental findings, which are clinically relevant genetic variants for disor ders unrelated to the reason for ordering the genetic testing. The decision of whether to pro vide information about incidental findings is complex because such results will have varying clinical validity (whether the genetic variant causes the disorder) and utility (whether effec tive medical treatment is available for the disor der). 3, 4 For example, although effective medical treatment may be available for some validated incidental findings, other incidental findings may not be validated as causing the disorder, and still others will be validated but not associated with effective treatment options.
To address in part the challenges surrounding the return of incidental findings, the American College of Medical Genetics and Genomics pub lished recommendations for reporting incidental findings from clinical sequencing. 5 The state ment lists a minimum of 56 genes that labora tories should examine, with results reported to patients through the managing physician. This list includes genes with highpenetrance muta tions (i.e., a high proportion of individuals with the mutation will exhibit clinical symptoms) val idated to be associated with disorders for which medical interventions are available.
Societal preferences for the return of incidental findings from clinical genomic sequencing: a discrete-choice experiment
Background: An important challenge with the application of next-generation sequencing technology is the possibility of uncovering incidental genomic findings. A paucity of evidence on personal utility for incidental findings has hindered clinical guidelines. Our objective was to estimate personal utility for complex information derived from incidental genomic findings.
Methods:
We used a discrete-choice experiment to evaluate participants' personal utility for the following attributes: disease penetrance, disease treatability, disease severity, carrier status and cost. Study participants were drawn from the Canadian public. We analyzed the data with a mixed logit model.
Results:
In total, 1200 participants completed our questionnaire (available in English and French). Participants valued receiving information about high-penetrance disorders but expressed disutility for receiving information on low-penetrance disorders. The average willingness to pay was $445 (95% confidence interval [CI] $322-$567) to receive incidental findings in a scenario where clinicians returned information about high-penetrance, medically treatable disorders, but only 66% of participants (95% CI 63%-71%) indicated that they would choose to receive information in that scenario. On average, participants placed an important value ($725, 95% CI $600-$850) on having a choice about what type of findings they would receive, including receipt of information about high-penetrance, treatable disorders or receipt of information about highpenetrance disorders with or without available treatment. The predicted uptake of that scenario was 76% (95% CI 72%-79%).
The original version of this statement did not "favour offering the patient a preference" for which results would be returned. The reasoning was that clinicians have a duty to prevent poten tial harm by telling patients about incidental findings. The working group that developed the recommendations further stated that it is imprac tical to provide the level of genetic counselling required for informed preference on all potential disorders. 5 As such, the working group recom mended that clinicians discuss with patients the possibility of receiving incidental findings from the list. It was argued that patient autonomy is preserved because patients can decline clinical sequencing if they prefer to not receive informa tion about incidental findings. 5 However, this rationale has been subject to debate because of its "allornone" nature, whereby patients must agree to receive information about incidental findings or clinical sequencing is not provided. [6] [7] [8] [9] In April 2014, in response to the ongoing debate, the statement was amended to include an "opt out" option for patients who do not want to receive information about incidental findings. 10 Notwithstanding the ethical debate, there is a lack of quantitative, preferencebased economic evidence for the return of incidental genomic findings. 8 It has been argued 8 that this gap in evi dence hindered development of the working group's recommendation statement. More gener ally, evidence on preferences for the return of incidental findings is crucial for health policy, for health systems planning and for informing future lists that may include "many more genes." 8 We aimed to generate evidence on the personal utility that study participants from the Canadian public ascribe to the return of inci dental genomic findings in the clinical setting. We chose participants from the general public because the public is the largest stakeholder in Canada's publicly funded health care system.
Methods
This study used a crosssectional design in which a sample of the Canadian public 18 years of age or older stated their preferences for the return of incidental findings from genomic sequencing. To elicit preferences between alternatives and to esti mate personal utility and willingness to pay, we used a discretechoice experiment. [11] [12] [13] [14] [15] [16] In genomic medicine, personal utility is the worth that an individual ascribes to a genomic test. 17 In economics, personal utility is quantified as a measure of wellbeing determined by eliciting individuals' choices between different goods. It is assumed that individuals assign preferences to alternative goods and choose the most preferred good from the list of available alternatives; from these choices, indirect utility can be estimated. 18 The discretechoice method begins by iden tifying the key characteristics (called attributes) of a technology. Attributes are defined across a range of levels that affect the benefit that individ uals will ascribe to a good. Experimental design techniques are then used to construct a series of choice tasks from combinations of the attribute levels (called scenario alternatives). Crucially, each task requires study participants to choose between 2 or more scenarios. The regression esti mates are then interpreted as the utilities associ ated with each respective attribute level 18 and are referred to as partworth utilities. Total utility is estimated by summing over combinations of the partworth utilities that describe a particular good. The inclusion of a cost attribute in the test description allows for a monetary estimate of utility, which is called willingness to pay.
Questionnaire development and administration
Development of the questionnaire has been described previously. 19 Briefly, we determined the attributes through literature review, consulta tion with experts and focus groups with patients undergoing genetic testing. We refined the ques tionnaire through pretest interviews 19 with patients who underwent conventional genetic testing for familial colorectal cancer or polyposis syndromes. We selected the levels of each attri bute according to their ability to accommodate a range of estimates that might be realized when incidental findings are returned. Each task included a choice between 2 alternatives (see Figure 1 for an example). A "no information" option was included to accommodate individuals who did not want to receive any information about incidental results.
We conducted a pilot study using a panCan adian sample of the public (n = 100). quences), carrier status (yes, no) and cost of receiving the results ($425, $750, $1000, $1500). The questionnaire was available in both French and English. The choicebased experimental design used Doptimal procedures to maximize the statistical efficiency of the model. 20, 21 This approach resulted in 80 choice tasks. Each par ticipant was randomly assigned to 1 of 5 blocks containing 16 choice tasks.
A professional survey organization adminis tered the questionnaire. The organization recruited participants using opportunistic sampling (e.g., through website popup messages) and through an Internet sampling panel of 295 983 Canad ians. Participants who met the criteria for age (≥ 18 years) and region of residence according to Canadian population characteristics were eli gible. Those who had participated in preference based research in the previous 6 months were excluded. Those who agreed to participate were referred to a passwordprotected website. The questionnaire contained an introduction asking participants to imagine that they had been diag nosed with a serious disease and would undergo genetic testing. The introduction also provided an education module outlining the concept of incidental findings and the attributes and levels of the choice tasks. The University of British Columbia Behavioural Research Ethics Board, BC Cancer Agency, approved the study.
Statistical analyses
We analyzed responses in Stata 12 software (StataCorp LP) using an errorcomponent mixed logit model. 22 This model allows for realistic estimates of the number of participants wanting information on incidental findings under various scenarios. 22 It can also accommo date preference heterogeneity by allowing esti mation of individualspecific utility values for receipt of results from incidental findings. The modelling approach requires specification of a distribution for each attribute level that is hypothesized to vary across participants. Parameters characterizing the mean and stan dard deviation of the heterogeneity distribution are estimated using maximum simulated likeli hood techniques. 11, 22 The estimated mean and standard deviation parameters characterize the distribution of individuallevel utility in the sampled population.
We used effects coding for each categorical attribute. We included cost as a continuous vari able. 14 We specified that attributes representing the threshold level for lifetime risk of disease, the treatability and severity of incidentally iden tified diseases, and information on carrier status would follow normal distributions. This allowed participants to have heterogeneous values for these attributes relative to the reference level. For example, for the 5% lifetime risk or higher attribute level, the normal distribution allowed participants to have positive or negative prefer ences about receiving this information. We speci fied the remaining attribute, cost, as fixed, to facilitate the statistical analysis. 11 We examined the predicted uptake and will ingness to pay for several scenarios related to the working group's statement (as depicted in Figure  2 ). Predicted uptake was based on an estimate of the percentage of the population predicted to choose a particular scenario. 13 We used the delta method to generate 95% confidence intervals (CIs) for these estimates.
Results
In total, 1200 of the 1965 individuals who responded to the email invitation completed all 16 choice questions (cooperation rate of 61%). Table 1 presents an overview of participants' sociodemographic characteristics, relative to the Canadian adult population.
Participants expressed positive utility for receipt of incidental findings about diseases with a lifetime risk of at least 80% or at least 90%, with recommended effective medical or lifestyle interventions available, and with severe health outcomes, as well as for receipt of information about carrier status (Table 2) . Disutility, or a reduction in wellbeing, was observed for inci dental findings associated with disorders with no medical or lifestyle intervention available. Par ticipants also expressed disutility for receiving information about disorders with mild health consequences and for a category in which inci dental findings for all diseases with lifetime risk of 5% or higher were returned.
We observed statistically significant prefer ence heterogeneity for the utility that participants placed on several types of incidental findings. For example, all else being equal, we predicted that 16% of the participants would have a nega tive value for receipt of information about inci dental findings for disorders with recommended effective medical treatment and lifestyle changes ( Table 2) . For carrier status, the model predicted that 42% of the sample would have a negative value for receiving this type of information.
Estimated willingness to pay and predicted uptake for alternative policy options are summa rized in Table 3 . Scenario 1 aligns with the work ing group's recommendations 5 (disorders with rec ommended medical treatment, 80% penetrance). The average willingness to pay for this scenario was $445 (95% CI $322-$567), and 66% of the participant population was predicted to find this scenario acceptable. The willingness to pay for scenario 2, the return of findings for which med ical and lifestyle interventions are recom mended, was $641 (95% CI $520-$762), with 73% of the population predicted to find the pol icy option to be acceptable. Scenario 3 examined the incremental willing ness to pay of offering participants a choice between receipt of information about disorders for which only medical treatment is available or receipt of information about all disorders, regardless of treatment availability, compared with receipt of information only for disorders with recommended effective medical treatment available, as recommended by the American College of Medical Genetics and Genomics. The incremental willingness to pay for this scenario was $280 (95% CI $248-$313), which indicates a net positive value for access to the extended menu of options. The predicted probability of participants choosing an alternative in which information would be provided about both med ically treatable and nontreatable disorders was 27%, whereas 49% of participants were pre dicted to choose the option of receiving inciden tal results only for medic ally treatable condi tions. The estimated average willingness to pay for return of information on disorders with med ical treatment available or information on all disorders, regardless of treatment availability, compared with returning no information was $725 (95% CI $600-$850), with a predicted uptake of 76%.
In a post hoc analysis, the sample was reweighted to better reflect the demographic characteristics of the Canadian population. We observed no differences in willingness to pay or in predicted uptake (details available from the authors).
Interpretation
This article presents evidence on the cost-benefit tradeoffs and personal utility that people ascribe to the receipt of information about incidental find ings from clinical genomic sequencing. These results indicate that to maximize benefit, individ uals' preferences for disclosure should be consid ered and evaluated on an individuallevel basis within a shared decisionmaking framework. Such an endeavour will require research into the best way to communicate the range of possible inci dental findings. 23 In relation to the statement of the American College of Medical Genetics and Genomics working group, 5 we found support for returning 30 However, that study did not examine willingness to pay or uptake of scen arios related to the statement of the working group. 5 Furthermore, it did not explicitly examine tradeoffs for returning results that did and did not have medical treatment available.
Limitations
Our study had a number of limitations. To deter mine utility, we engaged a professional survey organization to recruit a panCanadian sample of the population. Although great care was taken in recruiting the participants, unobservable charac teristics concerning participation in research of this type may introduce biases. We found statis tically significant differences in demographic characteristics between the study participants and the Canadian population. Participants had higher education than the Canadian population; they also tended to be in the middle income ranges ($30 000 to $59 999). However, in our post hoc analysis in which the sample was reweighted to more closely represent the Cana dian population, we observed no differences from our primary analysis. A second limitation related to the hypothetical nature of the choice task. We constructed an educational component for the discretechoice survey similar to what could be presented in the clinic setting. How ever, because participants in this study would not be bound by their choices, the discretechoice estimates may exhibit "hypothetical bias" (i.e., a difference between what people say they will choose and what they actually choose). In health economics, the criterion validity of discrete choice experiments has been previously demon strated, 31 but research has shown that predicted probabilities of choice are accurate in the aggre gate but not at the individual level. 32 
Conclusion
In Canada, health care policy is the jurisdiction of provincial and territorial ministries. Although use of economic evidence is not mandated, cost effectiveness and cost-benefit analyses are rec ommended for informing policy. 33 Cost-benefit analyses in particular are recommended when evaluating the personal utility of genomic tech nologies. 12, 34 There can exist a degree of discom fort in assigning an estimate to personal utility. 17 However, utility is essential for informing resource allocation decisions, 35 because a policy alternative is economically more efficient if the utility from a program outweighs its cost. This situation is different from the nonmalfeasance principle in medicine, which emphasizes avoid ing causing needless harm or injury according to reasonable standards.
Our results can be used to inform policy in the following ways. First, we estimated the prob ability of uptake related to several policy rec ommendations, which can be useful to predict demand for the return of incidental findings and as an input to economic decisionmodelling. Second, the willingnesstopay estimates can be used to inform reimbursement decisions. Third, the willingnesstopay estimates can be used in cost-benefit analyses to examine the allocation of health resources. 12 Finally, we found a diversity of interest about which incidental findings to return, if any. This result supports offering individual patients an informed choice about the types of incidental findings they prefer to receive.
